# Lyell Immunopharma, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Lyell Immunopharma, Inc.). ## Overview Lyell Immunopharma is a U.S.-based late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies for cancer. Its lead programs, including ronde-cel (LYL314) and LYL273, are designed to improve durability and response rates in hematologic malignancies and solid tumors, while the company also operates its own manufacturing center to control supply and quality. ## Products & services • ronde-cel (LYL314) dual-targeting CD19/CD20 CAR T-cell therapy • LYL273 CAR T-cell product candidate for advanced mCRC • Next-generation autologous CAR T-cell pipeline programs • LyFE Manufacturing Center cGMP cell therapy manufacturing • Process development, clinical supply and viral vector production - **Clinical CAR T-cell product candidates** (0%) — Autologous cell therapies in clinical development for hematologic malignancies and solid tumors. - **Manufacturing and supply capabilities** (0%) — Internal cGMP manufacturing for patient-specific CAR T-cell products and viral vectors. - **Research and process development** (0%) — Technology development, translational research and manufacturing process optimization for pipeline assets. - **Licensing and strategic collaboration activities** (0%) — Technology and asset access through acquisitions and license agreements that expand the pipeline. - ronde-cel (LYL314) dual-targeting CD19/CD20 CAR T-cell therapy - LYL273 CAR T-cell product candidate for advanced mCRC - Next-generation autologous CAR T-cell pipeline programs - LyFE Manufacturing Center cGMP cell therapy manufacturing - Process development, clinical supply and viral vector production ## Customers Lyell does not yet sell approved commercial products; its current 'customers' are primarily clinical trial patients, investigators, hospitals and treatment centers participating in its studies. In the future, if approved, its therapies would be used by oncologists and specialty cancer centers treating relapsed/refractory lymphoma and metastatic colorectal cancer. The company also relies on partners, licensors and clinical sites to execute development and manufacturing transitions. - **Clinical trial patients** (primary) — Patients with relapsed/refractory large B-cell lymphoma and advanced mCRC enrolled in trials to test safety and efficacy. - **Clinical investigators and trial sites** (primary) — Hospitals and oncology centers that administer study treatment, monitor outcomes and support enrollment. - **Future oncology treatment centers** (secondary) — Specialty centers that would prescribe and infuse approved CAR T products if Lyell reaches commercialization. - **Payers and reimbursement stakeholders** (secondary) — Insurers and other payors that will determine access and adoption for premium-priced cell therapies. - Clinical trial patients with relapsed/refractory LBCL and other cancers - Oncology investigators and hospitals running Lyell-sponsored studies - Specialty cancer centers that would use CAR T therapies if approved - Payers and insurers that will influence adoption and pricing after approval - Licensors and partners involved in pipeline access and manufacturing transfer ## Geography Lyell is headquartered and manufactures in the United States, with its LyFE Manufacturing Center in Bothell, Washington and a former West Hills facility that is being closed. The company’s disclosed operations are primarily U.S.-based, but its manufacturing design is intended to meet both U.S. and EU cGMP standards, supporting potential future international development and commercialization. Its LYL273 license excludes mainland China, Hong Kong, Macau and Taiwan, which creates a defined geographic boundary for that asset. - Headquartered in the United States and incorporated in 2018 - LyFE Manufacturing Center is in Bothell, Washington - West Hills facility closure reduced U.S. manufacturing footprint - Manufacturing designed to meet U.S. and EU cGMP standards - LYL273 license excludes mainland China, Hong Kong, Macau and Taiwan ## Strategy Lyell’s strategy is to build differentiated CAR T therapies with stronger potency and durability than first-generation products, starting with ronde-cel in large B-cell lymphoma and expanding into solid tumors with LYL273 and other programs. A central priority is to control manufacturing internally through LyFE, which is intended to improve supply reliability, reduce cost and protect proprietary process know-how. The company is also using acquisitions and licensing to broaden its pipeline and accelerate clinical development. - **Advance ronde-cel to potential approval** (short-term) — It is the lead asset and the main near-term value driver in LBCL. - **Transition manufacturing to LyFE** (short-term) — Internal manufacturing is intended to reduce supply risk and improve economics. - **Expand into solid tumors** (medium-term) — Solid tumors broaden the addressable market beyond hematologic cancers. - **Build a broader next-generation CAR T platform** (long-term) — Platform breadth can improve differentiation and support future partnerships or launches. - Advance ronde-cel through pivotal and Phase 1/2 trials - Develop LYL273 for advanced metastatic colorectal cancer - Use LyFE to control supply, quality and manufacturing timing - Expand the pipeline through acquisitions and licensing - Position for early commercial launch if programs are approved ## Risks Lyell is a pre-revenue clinical-stage company, so its business depends on successful trial outcomes, regulatory approvals and access to capital. Its internal manufacturing strategy reduces some supply-chain risk but also concentrates execution risk in a single facility and in technology transfers for ronde-cel and LYL273. Competition is intense, and approved therapies may be difficult to displace without clearly superior clinical data and reimbursement support. - **Clinical development failure** [critical] — Lead assets are still in trials and may not show sufficient safety or efficacy. - **Manufacturing and supply disruption** [high] — Patient-specific CAR T production is complex and any transfer or quality issue can delay trials. - **Capital needs and dilution** [high] — The company has substantial losses and no commercial revenue to fund operations. - **Competitive pressure** [high] — Approved CAR T therapies, bispecifics and other oncology drugs already have physician familiarity and payer coverage. - **Integration and acquisition risk** [medium] — ImmPACT and LYL273 integration may not deliver expected cost savings or pipeline benefits. - No approved products and no product sales yet - Clinical trial failure could eliminate lead program value - Manufacturing transfer and scale-up could disrupt supply - Needs to compete with established CAR T and other oncology drugs - May require additional capital to fund development and operations ## Accounting Lyell is a pre-commercial biotech, so reported results are driven mainly by R&D expense, manufacturing build-out and acquisition-related accounting rather than revenue recognition. Investors should watch fair value accounting for the SPA put/call instrument, acquisition-related estimates and any impairment or restructuring effects tied to facility closures and technology transfers. Because the company has no product revenue, small changes in clinical, manufacturing or financing assumptions can materially affect reported losses and balance-sheet values. - **Fair value of SPA put/call instrument** — Can affect other income/expense and net loss - **Acquisition accounting** — Can affect goodwill/intangibles, amortization and future impairment risk - **Restructuring and facility closure accounting** — Can affect operating expenses and cash outflows - **Clinical and manufacturing asset recoverability** — Potential impairment charges if programs or capacity plans change - No product revenue; results are dominated by R&D and G&A spend - Fair value measurement of the SPA put/call flows through earnings - Acquisition accounting for ImmPACT and LYL273 affects assets and liabilities - Facility closure and workforce reduction may create restructuring charges - Estimates for clinical and manufacturing assets can affect impairment risk --- *Last updated: 2026-04-28T20:23:39.240784+00:00*